Jefferies Downgrades VistaGen Therapeutics (VTGN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Price: $0.17 --0%
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Join SI Premium – FREE
Jefferies analyst Andrew Tsai downgraded VistaGen Therapeutics (NASDAQ: VTGN) from Buy to Hold with a price target of $0.20 (from $8.00).
For an analyst ratings summary and ratings history on VistaGen Therapeutics click here. For more ratings news on VistaGen Therapeutics click here.
Shares of VistaGen Therapeutics closed at $1.07 yesterday.
You May Also Be Interested In
- BofA Downgrades Marvell (MRVL) to Neutral
- Strategy (MSTR) PT Lowered to $180 at B.Riley
- Checkpoint Software (CHKP) PT Raised to $135 at Wells Fargo
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
